

Our Docket: 19491

WO 2005/004990

1/15

Fig. 1: Feed and drink intake in the observation period





^{*} p<0.05 vs. control


Jobst Krauskopf, et al. USE OF WHEY PERMEATE FOR THE TREATMENT OF METABOLIC SYNDROME

Our Docket: 19491

2/15

WO 2005/004990


Fig. 2: Body mass and blood glucose concentration in the observation period (7 days before the start of treatment and up to 42 days of treatment)




3/15

PCT/EP2004/007690

Fig. 3a: Concentration of NEFA (non-esterified fatty acids) and insulin before the start of treatment, after 3 weeks and after 6 weeks of treatment $_{mean \pm SD}$






° p<0.05 vs. day 0 °° p<0.01 vs. day 0


Jobst Krauskopf, et al. USE OF WHEY PERMEATE FOR THE TREATMENT OF METABOLIC SYNDROME Our Docket: 19491

WO 2005/004990

4/15


Fig. 3b: Concentrations of total and HDL cholesterol before the start of treatment, after 3 weeks and after 6 weeks of treatment, $_{mean \pm SD}$






5/15

Fig. 3c: Concentrations of LDL cholesterol and triglycerides before the start of treatment, after 3 weeks and after 6 weeks of treatment



6/15

Fig. 3d: Concentrations of C-reactive protein before the start of treatment, after 3 weeks and after 6 weeks of treatment, mean ± SD




Our Docket: 19491

WO 2005/004990

PCT/EP2004/007690

7/15

Fig. 3e: Number of leucocytes in 6-week observation period



Jobst Krauskopf, et al. USE OF WHEY PERMEATE FOR THE TREATMENT OF METABOLIC SYNDROME


Our Docket: 19491


WO 2005/004990

PCT/EP2004/007690

8/15

Fig. 4a: Blood glucose curve in the oGTT and glucose excess areas before the start of treatment







mean ± SD

9/15


Fig. 4b: Curve of the insulin concentrations in the oGTT and insulin excess areas before the start of treatment






10/15


Fig. 5a: Blood glucose curve in the oGTT and glucose excess areas after 3 weeks of treatment






11/15

Fig. 5b: Curve of the insulin concentrations in the oGTT and insuline excess areas after 3 weeks of treatment







12/15

PCT/EP2004/007690

Fig. 6a: Blood glucose curve in the oGTT and glucose excess areas after 6 weeks of treatment





mean \pm SD * p<0.05 vs. control ** p<0.01 vs. control


Jobst Krauskopf, et al. USE OF WHEY PERMEATE FOR THE TREATMENT OF METABOLIC SYNDROME


Our Docket: 19491

WO 2005/004990

13/15

Fig. 6b: Curve of the insulin concentrations in the oGTT and insulin excess areas after 6 weeks of treatment







PCT/EP2004/007690

14/15

Fig. 7: Diurnal glood glucose and lactate profile before the start of treatment






Our Docket: 19491


WO 2005/004990

PCT/EP2004/007690

15/15

Fig. 8: Diurnal blood glucose and lactate profile after 6 weeks of treatment





^{**} p<0.01 vs. control